Do higher drug costs lead to better health? – A rebuttal
Main Article Content
Keywords
LETTER TO THE EDITOR
Abstract
The authors Mintzes and Lexchin1 in their commentary to our paper titled The Value of Medicines in Canada,2 have cultivated a theme to which we both agree – the need for efficient use of drug therapy. It is our original position that innovative pharmaceuticals, when used appropriately as part of overall disease management, offer value-for-money by increasing both the global quality and quantity of life
References
1. Mintzes B, Lexchin J. Do Higher Drug Costs Lead to Better Health? Can J Clin Pharmacol 2005;12(1):e22-e27.
2. Han D, Wang ECY. The Value of Medicines in Canada. Can J Clin Pharmacol 2005;12 (1):e10- e21.
3. Canadian Institute for Health Information. National health expenditure trends, 1975-2002. Ottawa, ON: CIHI, 2002.
4. Policy Research Division, Strategic Policy Directorate, Population and Public Health Branch, Health Canada. Economic burden of illness in Canada, 1998.2002.
5. Guide to Community Preventive Services. http://www.thecommunityguide.org Accessed December 15, 2003.
6. Canadian Task Force on Preventive Health Care. http://www.ctfphc.org. Accessed January, 2005.
7. Patented Medicines Pricing Review Board. Annual Report 2003. Available at http://pmprb.com/english/View.asp?x=302&mp=91 Accessed January, 2005
8. Calfee, JE. Prices, Markets, and the Pharmaceutical Revolution. Washington DC: American Enterprise Institute Press, 2000.
9. DiMasi J, Paquette C. The Economics of Follow-on Drug Research and Development Trends in Entry Rates and the Timing of Development. Pharmacoeconomics 2004;22(Suppl.2):1-14.
10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003;22(2):151-185
2. Han D, Wang ECY. The Value of Medicines in Canada. Can J Clin Pharmacol 2005;12 (1):e10- e21.
3. Canadian Institute for Health Information. National health expenditure trends, 1975-2002. Ottawa, ON: CIHI, 2002.
4. Policy Research Division, Strategic Policy Directorate, Population and Public Health Branch, Health Canada. Economic burden of illness in Canada, 1998.2002.
5. Guide to Community Preventive Services. http://www.thecommunityguide.org Accessed December 15, 2003.
6. Canadian Task Force on Preventive Health Care. http://www.ctfphc.org. Accessed January, 2005.
7. Patented Medicines Pricing Review Board. Annual Report 2003. Available at http://pmprb.com/english/View.asp?x=302&mp=91 Accessed January, 2005
8. Calfee, JE. Prices, Markets, and the Pharmaceutical Revolution. Washington DC: American Enterprise Institute Press, 2000.
9. DiMasi J, Paquette C. The Economics of Follow-on Drug Research and Development Trends in Entry Rates and the Timing of Development. Pharmacoeconomics 2004;22(Suppl.2):1-14.
10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003;22(2):151-185
Article Sidebar
Published
Dec 8, 2018
Article Details
How to Cite
Han, D., & Wang, E. C. Y. (2018). Do higher drug costs lead to better health? – A rebuttal. Journal of Population Therapeutics and Clinical Pharmacology, 12(1). Retrieved from https://jptcp.com/index.php/jptcp/article/view/87
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.